Sean Brynjelsen sold $3.6M of ETON
President & CEO at Eton Pharmaceuticals, Inc.. 210,000 shares at an average of $17.11, traded Jun 3, 2025, filed Jun 5, 2025.
Score components
- +25RoleCEO
- +25Trade size$3.6M at market
- 0Share of holdings soldSold 6.8% of holdings
- +8Cluster2 insiders selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -16.2%, 3m +3.6%, 6m -2.6%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001437749-25-019583, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jun 3, 2025 | SOpen-market sale Common Stock | -60,945 | $17.38 | $1.1M | 3,022,568 | Jun 5, 2025 |
| Jun 3, 2025 | SOpen-market sale Common Stock | -8,655 | $18.38 | $159k | 3,013,913 | Jun 5, 2025 |
| Jun 3, 2025 | SOpen-market sale Common Stock | -400 | $19.02 | $7,608 | 3,013,513 | Jun 5, 2025 |
| Jun 4, 2025 | SOpen-market sale Common Stock | -70,000 | $17.00 | $1.2M | 2,943,513 | Jun 5, 2025 |
| Jun 5, 2025 | SOpen-market sale Common Stock | -70,000 | $16.81 | $1.2M | 2,873,513 | Jun 5, 2025 |
Related signals
Other insiders at Eton Pharmaceuticals, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 13Weak | ETONsell Eton Pharmaceuticals, Inc. | David Krempa Chief Business Officer | $229k 4,166 shares | -9% | |
| 50Moderate | Eton Pharmaceuticals, Inc. | Paul Maier V director | $3.0M 50,000 shares | -46% | |
| 50Moderate | Eton Pharmaceuticals, Inc. | Paul Maier V director | $3.0M 50,000 shares | -46% | |
| 50Moderate | Eton Pharmaceuticals, Inc. | David Krempa Chief Business Officer | $1.6M 25,000 shares | -40% | |
| 65Notable | Eton Pharmaceuticals, Inc. | Sean Brynjelsen President & CEO | $6.1M 100,000 shares | -9% | |
| 37Weak | ETONsell Eton Pharmaceuticals, Inc. | Opaleye Management Inc. owner | $1.1M 28,315 shares | -1% | |
| 37Weak | ETONsell Eton Pharmaceuticals, Inc. | Opaleye Management Inc. owner | $1.1M 28,315 shares | -1% | |
| 37Weak | ETONsell Eton Pharmaceuticals, Inc. | Opaleye Management Inc. owner | $4.8M 126,685 shares | -5% | |
| 45Moderate | ETONsell Eton Pharmaceuticals, Inc. | Jennifer McKie Adams director | $1.6M 50,000 shares | -100% | |
| 63Notable | Eton Pharmaceuticals, Inc. | Sean Brynjelsen President & CEO | $3.8M 120,000 shares | -13% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.